| 2021 | Genomic landscape of extraordinary responses in metastatic breast cancer
| COMMUNICATIONS BIOLOGY |
| 2016 | Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
| JOURNAL OF BREAST CANCER |
| 2020 | Intermediate HER2 Expression Is Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancer Patients Aged 55 Years and Older | BREAST CANCER RESEARCH AND TREATMENT |
| 2018 | Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective | CLINICAL BREAST CANCER |
| 2016 | Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
| PLOS ONE |
| 2011 | Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer | ONCOLOGY |
| 2013 | Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
| ANNALS OF ONCOLOGY |
| 2017 | Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results
| ANNALS OF SURGICAL TREATMENT AND RESEARCH |
| 2020 | O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity
| PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA |
| 2023 | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
| BREAST CANCER RESEARCH |
| 2012 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
| PLOS ONE |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2020 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2013 | Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer | BREAST |
| 2021 | Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
| FRONTIERS IN ONCOLOGY |
| 2008 | Role of sonography in the detection of contralateral metachronous breast cancer in an Asian population | AMERICAN JOURNAL OF ROENTGENOLOGY |
| 2013 | S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
| BMC CANCER |
| 2009 | Sonographic surveillance for the detection of contralateral metachronous breast cancer in an Asian population | AMERICAN JOURNAL OF ROENTGENOLOGY |
| 2006 | The changes of estrogen receptor-β variants expression in breast carcinogenesis: Decrease of estrogen receptor-β2 expression is the key event in breast cancer development | JOURNAL OF SURGICAL ONCOLOGY |
| 2009 | US surveillance of regional lymph node recurrence after breast cancer surgery. | RADIOLOGY |
| 2015 | 성장인자수용체-2 양성 유방암 조직에서 표적치료 전후의 성장인자수용체군 발현양상
| Korean Journal of Clinical Oncology (대한임상종양학회지) |
| 2005 | 예후결정인자를 고려한 갑상선 미소암(微小癌)의 임상상
| Korean Journal of Medicine (대한내과학회지) |
